{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T17:33:48Z","timestamp":1776447228355,"version":"3.51.2"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2020,4,15]],"date-time":"2020-04-15T00:00:00Z","timestamp":1586908800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,4,15]],"date-time":"2020-04-15T00:00:00Z","timestamp":1586908800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1007\/s10072-020-04387-5","type":"journal-article","created":{"date-parts":[[2020,4,15]],"date-time":"2020-04-15T19:02:45Z","timestamp":1586977365000},"page":"2255-2257","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Exacerbation of myasthenia gravis after amoxicillin therapy: a case series"],"prefix":"10.1007","volume":"41","author":[{"given":"Veria","family":"Vacchiano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piergiorgio","family":"Solli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilaria","family":"Bartolomei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Lai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rocco","family":"Liguori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabrizio","family":"Salvi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,4,15]]},"reference":[{"issue":"13","key":"4387_CR1","doi-asserted-by":"publisher","first-page":"e25","DOI":"10.1056\/NEJMc1701027","volume":"376","author":"NE Gilhus","year":"2017","unstructured":"Gilhus NE (2017) Myasthenia gravis. N Engl J Med 376(13):e25","journal-title":"N Engl J Med"},{"issue":"6","key":"4387_CR2","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1007\/s10072-019-03746-1","volume":"40","author":"A Evoli","year":"2019","unstructured":"Evoli A, Antonini G, Antozzi C, DiMuzio A, Habetswallner F, Iani C et al (2019) Italian recommendations for the diagnosis and treatment of myasthenia gravis. Neurol Sci 40(6):1111\u20131124","journal-title":"Neurol Sci"},{"issue":"10","key":"4387_CR3","doi-asserted-by":"publisher","first-page":"839","DOI":"10.2165\/11593110-000000000-00000","volume":"34","author":"SC Jones","year":"2011","unstructured":"Jones SC, Sorbello A, Boucher RM (2011) Fluoroquinolone-associated myasthenia gravis exacerbation: evaluation of postmarketing reports from the US FDA adverse event reporting system and a literature review. Drug Saf 34(10):839\u2013847","journal-title":"Drug Saf"},{"issue":"12","key":"4387_CR4","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1212\/01.wnl.0000247741.72466.8c","volume":"67","author":"X Perrot","year":"2006","unstructured":"Perrot X, Bernard N, Vial C, Antoine JC, Laurent H, Vial T et al (2006) Myasthenia gravis exacerbation or unmasking associated with telithromycin treatment. Neurology 67(12):2256","journal-title":"Neurology"},{"issue":"6","key":"4387_CR5","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1002\/j.1875-9114.1997.tb03085.x","volume":"17","author":"RW Barrons","year":"1997","unstructured":"Barrons RW (1997) Drug-induced neuromuscular blockade and myasthenia gravis. Pharmacotherapy. 17(6):1220\u20131232","journal-title":"Pharmacotherapy."},{"issue":"1","key":"4387_CR6","first-page":"18","volume":"39","author":"AB Sonawalla","year":"1989","unstructured":"Sonawalla AB, Lance JW (1989) Relapse of myasthenia gravis after amoxycillin therapy. J Pak Med Assoc 39(1):18\u201319","journal-title":"J Pak Med Assoc"},{"issue":"3","key":"4387_CR7","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1001\/archneur.1986.00520030045010","volume":"43","author":"Z Argov","year":"1986","unstructured":"Argov Z, Brenner T, Abramsky O (1986) Ampicillin may aggravate clinical and experimental myasthenia gravis. Arch Neurol 43(3):255\u2013256","journal-title":"Arch Neurol"},{"issue":"1","key":"4387_CR8","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1111\/j.1399-6576.2011.02564.x","volume":"56","author":"P Gritti","year":"2012","unstructured":"Gritti P, Sgarzi M, Carrara B, Lanterna LA, Novellino L, Spinelli L et al (2012) A standardized protocol for the perioperative management of myasthenia gravis patients. Experience with 110 patients. Acta Anaesthesiol Scand 56(1):66\u201375","journal-title":"Acta Anaesthesiol Scand"},{"issue":"6","key":"4387_CR9","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1007\/s00415-018-8751-9","volume":"265","author":"NE Gilhus","year":"2018","unstructured":"Gilhus NE, Romi F, Hong Y, Skeie GO (2018) Myasthenia gravis and infectious disease. J Neurol 265(6):1251\u20131258","journal-title":"J Neurol"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-020-04387-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-020-04387-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-020-04387-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,4]],"date-time":"2024-08-04T02:44:24Z","timestamp":1722739464000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-020-04387-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,15]]},"references-count":9,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["4387"],"URL":"https:\/\/doi.org\/10.1007\/s10072-020-04387-5","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,15]]},"assertion":[{"value":"29 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"V. Vacchiano, P. Solli, I. Bartolomei, G. Lai, and F. Salvi report no disclosures.R. Liguori reports personal fees from Biogen, Sanofi Genzyme, Argon Healthcare s.r.l., Amicus Therapeutics s.r.l., and Alfasigma for advisory board consultancy and lecture fees from Dynamicom Education, SIMG Service, Adnkronos Salute Unipersonale s.r.l., and DOC Congress s.r.l. outside the submitted work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}